MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ph19010079

Медицинская библиотека · Pharmaceuticals (Basel, Switzerland) · 2025

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Alexeeva Ekaterina I, Dvoryakovskaya Tatiana M, Nikishina Irina P, Zholobova Elena S, Matkava Valeriya G, Krekhova Elizaveta A, Raupov Rinat K, Bukhanova Daria V, Egorova Alina N, Grishin Sergey A, Samsonov Mikhail Yu, Kostik Mikhail M

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA) who had an inadequate response or intolerance to methotrexate (MTX).

Methods

We analyzed results from an open-label, single-arm trial of OKZ therapy at a dose of 64 mg every 4 weeks for 24 weeks. We evaluated pharmacokinetic (PK) parameters, clinical effectiveness, serum C-reactive protein (CRP) dynamics, and adverse events (AEs).

Results

Sixteen patients were included in the study, of whom 13 (81.2%) received OKZ through Week 24. The PK profile was consistent with observations in adults with rheumatoid arthritis (RA). By Week 16, 12 (80%) patients achieved an ACRpedi30 response, 11 (73.3%) achieved an ACRpedi50 response, and 2 (13.3%) reached inactive disease status. This response was sustained through Week 24, and no disease flares were observed. A trend toward a better response was noted among patients with baseline CRP > 10 mg/L, higher baseline IL-6, and those naïve to biologic DMARDs. Twelve patients (75.0%) experienced twenty-three mild or moderate AEs. Infections were the most frequent AEs (in 6 patients, 37.5%). No serious AEs or deaths occurred.

Conclusions

OKZ treatment reduced pJIA disease activity and was well tolerated. The safety profile was consistent with that of other IL-6 inhibitors, and the PK profile matched that seen in adult RA patients.

Для цитирования: Alexeeva Ekaterina I, Dvoryakovskaya Tatiana M, Nikishina Irina P, Zholobova Elena S, Matkava Valeriya G, Krekhova Elizaveta A, Raupov Rinat K, Bukhanova Daria V, Egorova Alina N, Grishin Sergey A, Samsonov Mikhail Yu, Kostik Mikhail M. Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.. Pharmaceuticals (Basel, Switzerland). 2025. DOI: 10.3390/ph19010079.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.